Abstract:Proximal spinal muscular atrophy (SMA) is a leading genetic cause for infant death in the world and results from the selective loss of motor neurons in the spinal cord. SMA is a consequence of low levels of SMN protein and small molecules that can increase SMN expression are of considerable interest as potential therapeutics. Previous studies have shown that both 4-phenylbutyrate (4PBA) and trichostatin A (TSA) increase SMN expression in dermal fibroblasts derived from SMA patients. AR42 is a 4PBA-tethered TSA derivative that is a very potent histone deacetylase inhibitor. SMA patient fibroblasts were treated with either AR42, AR19 (a related analogue), 4PBA, TSA or vehicle for 5 days and then immunostained for SMN localization. AR42 as well as 4PBA and TSA increased the number of SMN-positive nuclear gems in a dose-dependent manner while AR19 did not show marked changes in gem numbers. While gem number was increased in AR42-treated SMA fibroblasts, there were no significant changes in FL-SMN mRNA or SMN protein. The neuroprotective effect of this compound was then assessed in SMNΔ7 SMA (SMN2+/+;SMNΔ7+/+;mSmn-/-) mice. Oral administration of AR42 prior to disease onset increased the average lifespan of SMNΔ7 SMA mice by ~ 27% (20.1 ± 1.6 days for AR42-treated mice vs. 15.8 ± 0.4 days for vehicle-treated mice). AR42 treatment also improved motor function in these mice. AR42 treatment inhibited histone deacetylase (HDAC) activity in treated spinal cord although it did not affect SMN protein expression in these mice. AKT and GSK3β phosphorylation were both significantly increased in SMNΔ7 SMA mouse spinal cords. In conclusion, presymptomatic administration of the HDAC inhibitor AR42 ameliorates the disease phenotype in SMNΔ7 SMA mice in a SMN-independent manner possibly by increasing AKT neuroprotective signaling.

Molecular Mechanisms and Therapeutics for SBMA/Kennedy's Disease

Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (SBMA)

The Research Advances of Kennedy Disease

Skeletal Muscle in Motor Neuron Diseases: Therapeutic Target and Delivery Route for Potential Treatments

[In Vitro Aggregation and Cellular Toxicity of Mutant Androgen Receptor Protein in Spinal and Bulbar Muscular Atrophy].

Transcriptional Profile of Muscle following Acute Induction of Symptoms in a Mouse Model of Kennedy's Disease/Spinobulbar Muscular Atrophy

ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor

[Transcriptional Regulation and Subcellular Localization of Mutant Androgen Receptor in Spinal and Bulbar Muscular Atrophy].

Widespread Nuclear and Cytoplasmic Accumulation of Mutant Androgen Receptor in SBMA Patients.

Ligand-free Mitochondria-Localized Mutant AR-induced Cytotoxicity in Spinal Bulbar Muscular Atrophy

Sodium Butyrate Ameliorates Phenotypic Expression in a Transgenic Mouse Model of Spinal and Bulbar Muscular Atrophy

Polyglutamine expansion induced dynamic misfolding of Androgen Receptor

One case of spinal bulbar muscular atrophy misdiagnosed as polymyositis: Case report

Molecular Mechanisms and Animal Models of Spinal Muscular Atrophy.

Evaluation of the orally bioavailable 4-phenylbutyrate-tethered trichostatin A analogue AR42 in models of spinal muscular atrophy

Central neurodegeneration in Kennedy's disease accompanies peripheral motor dysfunction

Disease Mechanisms and Therapeutic Approaches in SMARD1—Insights from Animal Models and Cell Models

Combination of PCR Fragment Sequencing and Genotyping for The Diagnosis of Kennedy's Disease

Antagonistic effect of cyclin-dependent kinases and a calcium-dependent phosphatase on polyglutamine-expanded androgen receptor toxic gain of function

Advances and limitations for the treatment of spinal muscular atrophy

Current and emerging targeted therapies for spinal muscular atrophy